Bristol Myers Squibb

News

BMS pays $200m to expand Evotec alliance on protein degrader...

Bristol-Myers Squibb's Celgene unit has clearly been impressed by progress in its four-year-old alliance with Evotec on protein degradation.

News

BMS bags FDA okay for cardiomyopathy drug mavacamten

Bristol-Myers Squibb's has become the first company to bring a cardiac myosin inhibitor through to FDA approval, claiming a green light from the US regulator for mavacamten as a therapy for

News

End of the line for BMS, Nektar's bempegaldesleukin/Opdivo a...

Four years after Bristol-Myers Squibb paid $1.85 billion upfront to make Nektar's bempegaldesleukin a companion drug to its cancer immunotherapy Opdivo, the alliance is being discontinued.<

News

Cytokinetics' heart drug omecamtiv strikes out in heart fail...

Cytokinetics' hopes of resurrecting cardiac myosin activator omecamtiv mecarbil have suffered another setback, after the drug failed to show a benefit in a phase 3 heart failure study.

News

Gilead beats BMS to FDA okay for early lymphoma CAR-T therap...

Gilead Sciences' Kite Pharma has become the first drugmaker to get FDA approval to use a CAR-T therapy after just one earlier systemic therapy, moving the approach up the treatment pathway.

News

CHMP backs J&J's myeloma CAR-T therapy Carvykti

Johnson & Johnson is in course for approval of its multiple myeloma CAR-T therapy Carvykti in the EU the next few weeks, after getting a green light from the EMA's human medicines commi

BMS pays $200m to expand Evotec alliance on protein degrader...

BMS bags FDA okay for cardiomyopathy drug mavacamten

End of the line for BMS, Nektar's bempegaldesleukin/Opdivo a...

Cytokinetics' heart drug omecamtiv strikes out in heart fail...

Gilead beats BMS to FDA okay for early lymphoma CAR-T therap...

CHMP backs J&J's myeloma CAR-T therapy Carvykti

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Bristol Myers Squibb

Editor's Picks